{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:37:25Z","timestamp":1793813845781,"version":"4.6.1"},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"10","license":[{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2019-0194_s_999_w2aab3b7d120b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Discriminating <jats:italic>Mycoplasma pneumoniae<\/jats:italic> (MP) from <jats:italic>Streptococcus pneumoniae<\/jats:italic> (SP) and viral etiologies of community-acquired pneumonia (CAP) is challenging but has important implications regarding empiric antibiotic therapy. We investigated patient parameters upon hospital admission to predict MP infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0194_s_998_w2aab3b7d120b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All patients hospitalized in a tertiary care hospital between 2013 and 2017 for CAP with a confirmed etiology were analyzed using logistic regression analyses and area under the receiver operator characteristics (ROC) curves (AUC) for associations between demographic, clinical and laboratory features and the causative pathogen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0194_s_997_w2aab3b7d120b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We analyzed 568 patients with CAP, including 47 (8%) with MP; 152 (27%) with SP and 369 (65%) with influenza or other viruses. Comparing MP and SP by multivariate logistic regression analysis, younger age (odds ration [OR] 0.56 per 10 years, 95% CI 0.42\u20130.73), a lower neutrophil\/lymphocyte ratio (OR 0.9, 0.82\u20130.99) and an elevated C-reactive protein\/procalcitonin (CRP\/PCT) ratio (OR 15.04 [5.23\u201343.26] for a 400 mg\/\u03bcg cut-off) independently predicted MP. With a ROC curve AUC of 0.91 (0.80 for the &gt;400 mg\/\u03bcg cutoff), the CRP\/PCT ratio was the strongest predictor of MP vs. SP. The discriminatory value resulted from significantly lower PCT values (p\u2009&lt;\u20090.001) for MP, while CRP was high in both groups (p\u2009=\u20090.057). Comparing MP and viral infections showed similar results with again the CRP\/PCT ratio providing the best information (AUC 0.83; OR 5.55 for the &gt;400 mg\/\u03bcg cutoff, 2.26\u201313.64).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0194_s_996_w2aab3b7d120b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients hospitalized with CAP, a high admission CRP\/PCT ratio predicts <jats:italic>M. pneumoniae<\/jats:italic> infection and may improve empiric management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2019-0194","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T23:58:27Z","timestamp":1558828707000},"page":"1638-1646","source":"Crossref","is-referenced-by-count":24,"title":["A high C-reactive protein\/procalcitonin ratio predicts <i>Mycoplasma pneumoniae<\/i> infection"],"prefix":"10.1515","volume":"57","author":[{"given":"Olivia L.","family":"Neeser","sequence":"first","affiliation":[{"name":"Department of General Internal and Emergency Medicine, Medical University Clinic of the University of Basel , University Department of Medicine, Kantonsspital Aarau , Tellstr. 25 , 5001 Aarau , Switzerland , Phone: +41 62 838 57 93, Fax: +41 62 838 98 73"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Vukajlovic","sequence":"additional","affiliation":[{"name":"Department of General Internal and Emergency Medicine , Medical University Clinic of the University of Basel , Kantonsspital Aarau , Aarau , Switzerland"},{"name":"University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Felder","sequence":"additional","affiliation":[{"name":"Department of General Internal and Emergency Medicine , Medical University Clinic of the University of Basel , Kantonsspital Aarau , Aarau , Switzerland"},{"name":"University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haubitz","sequence":"additional","affiliation":[{"name":"Department of General Internal and Emergency Medicine , Medical University Clinic of the University of Basel , Kantonsspital Aarau , Aarau , Switzerland"},{"name":"Department of Infectious Diseases and Hospital Hygiene , Medical University Clinic of the University of Basel , Kantonsspital Aarau , Aarau , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Hammerer-Lercher","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Kantonsspital Aarau , Aarau , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Ottiger","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Kantonsspital Aarau , Aarau , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of General Internal and Emergency Medicine , Medical University Clinic of the University of Basel , Kantonsspital Aarau , Aarau , Switzerland"},{"name":"University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schuetz","sequence":"additional","affiliation":[{"name":"Department of General Internal and Emergency Medicine , Medical University Clinic of the University of Basel , Kantonsspital Aarau , Aarau , Switzerland"},{"name":"University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph A.","family":"Fux","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Hygiene, Medical University Clinic of the University of Basel , University Department of Medicine, Kantonsspital Aarau , Tellstr. 25 , 5001 Aarau , Switzerland , Phone: +41 62 838 68 18, Fax: +41 62 838 69 46"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"2023033110193596755_j_cclm-2019-0194_ref_001_w2aab3b7d120b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Nir-Paz R, Saraya T, Shimizu T, Van Rossum A, Bebear C. Editorial: Mycoplasma pneumoniae clinical manifestations, microbiology, and immunology. Front Microbiol 2017;8:1916.","DOI":"10.3389\/fmicb.2017.01916"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_002_w2aab3b7d120b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007;175:1086\u201393.","DOI":"10.1164\/rccm.200603-350OC"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_003_w2aab3b7d120b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Lenglet A, Herrador Z, Magiorakos AP, Leitmeyer K, Coulombier D, European Working Group on Mycoplasma pneumoniae s.Surveillance status and recent data for Mycoplasma pneumoniaeinfections in the European Union and European Economic Area, January 2012. Euro Surveill 2012;17:2.","DOI":"10.2807\/ese.17.05.20075-en"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_004_w2aab3b7d120b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Izumikawa K. Clinical features of severe or fatal Mycoplasma pneumoniae pneumonia. Front Microbiol 2016;7:800.","DOI":"10.3389\/fmicb.2016.00800"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_005_w2aab3b7d120b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Parrott GL, Kinjo T, Fujita J. A compendium for Mycoplasma pneumoniae. Front Microbiol 2016;7:513.","DOI":"10.3389\/fmicb.2016.00513"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_006_w2aab3b7d120b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Miyashita N, Obase Y, Ouchi K, Kawasaki K, Kawai Y, Kobashi Y, et al. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol 2007;56(Pt 12):1625\u20139.","DOI":"10.1099\/jmm.0.47119-0"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_007_w2aab3b7d120b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014;371:1619\u201328.","DOI":"10.1056\/NEJMra1312885"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_008_w2aab3b7d120b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. Adults. N Engl J Med 2015;373:415\u201327.","DOI":"10.1056\/NEJMoa1500245"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_009_w2aab3b7d120b1b6b1ab2b2b9Aa","unstructured":"van Gageldonk-Lafeber AB, Wever PC, van der Lubben IM, de Jager CP, Meijer A, de Vries MC, et al. The aetiology of community-acquired pneumonia and implications for patient management. Neth J Med 2013;71:418\u201325."},{"key":"2023033110193596755_j_cclm-2019-0194_ref_010_w2aab3b7d120b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Capelastegui A, Espana PP, Bilbao A, Gamazo J, Medel F, Salgado J, et al. Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis 2012;12:134.","DOI":"10.1186\/1471-2334-12-134"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_011_w2aab3b7d120b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Templeton KE, Scheltinga SA, van den Eeden WC, Graffelman AW, van den Broek PJ, Claas EC. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005;41:345\u201351.","DOI":"10.1086\/431588"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_012_w2aab3b7d120b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Huijskens EG, van Erkel AJ, Palmen FM, Buiting AG, Kluytmans JA, Rossen JW. Viral and bacterial aetiology of community-acquired pneumonia in adults. Influenza Other Respir Viruses 2013;7:567\u201373.","DOI":"10.1111\/j.1750-2659.2012.00425.x"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_013_w2aab3b7d120b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010;50:202\u20139.","DOI":"10.1086\/648678"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_014_w2aab3b7d120b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995;50:543\u20137.","DOI":"10.1136\/thx.50.5.543"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_015_w2aab3b7d120b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Bergin SP, Tsalik EL. Procalcitonin: The right answer but to which question? Clin Infect Dis 2017;65:191\u20133.","DOI":"10.1093\/cid\/cix323"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_016_w2aab3b7d120b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 2017;65:183\u201390.","DOI":"10.1093\/cid\/cix317"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_017_w2aab3b7d120b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Menendez R, Sahuquillo-Arce JM, Reyes S, Martinez R, Polverino E, Cilloniz C, et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2012;141:1537\u201345.","DOI":"10.1378\/chest.11-1446"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_018_w2aab3b7d120b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Kruger S, Ewig S, Papassotiriou J, Kunde J, Marre R, von Baum H, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009;10:65.","DOI":"10.1186\/1465-9921-10-65"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_019_w2aab3b7d120b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Johansson N, Kalin M, Backman-Johansson C, Larsson A, Nilsson K, Hedlund J. Procalcitonin levels in community-acquired pneumonia \u2013 correlation with aetiology and severity. Scand J Infect Dis 2014;46:787\u201391.","DOI":"10.3109\/00365548.2014.945955"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_020_w2aab3b7d120b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010;138:121\u20139.","DOI":"10.1378\/chest.09-2920"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_021_w2aab3b7d120b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Julian-Jimenez A, Timon Zapata J, Laserna Mendieta EJ, Parejo Miguez R, Flores Chacartegui M, Gallardo Schall P. [Ability of procalcitonin to predict bacteremia in patients with community acquired pneumonia]. Med Clin (Barc) 2014;142:285\u201392.","DOI":"10.1016\/j.medcli.2013.05.046"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_022_w2aab3b7d120b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Zhydkov A, Christ-Crain M, Thomann R, Hoess C, Henzen C, Werner Z, et al. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. Clin Chem Lab Med 2015;53:559\u201366.","DOI":"10.1515\/cclm-2014-0456"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_023_w2aab3b7d120b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006;34:2596\u2013602.","DOI":"10.1097\/01.CCM.0000239116.01855.61"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_024_w2aab3b7d120b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"de Jager CP, de Wit NC, Weers-Pothoff G, van der Poll T, Wever PC. Procalcitonin kinetics in Legionella pneumophila pneumonia. Clin Microbiol Infect 2009;15:1020\u20135.","DOI":"10.1111\/J.1469-0691.2009.02773.X"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_025_w2aab3b7d120b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Schuetz P, Hausfater P, Amin D, Haubitz S, Fassler L, GrolimundE, et al. Optimizing triage and hospitalization in adult general medical emergency patients: the triage project. BMC Emerg Med 2013;13:12.","DOI":"10.1186\/1471-227X-13-12"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_026_w2aab3b7d120b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600\u20137.","DOI":"10.1016\/S0140-6736(04)15591-8"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_027_w2aab3b7d120b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Loens K, Ieven M. Mycoplasma pneumoniae: current knowledge on nucleic acid amplification techniques and serological diagnostics. Front Microbiol 2016;7:448.","DOI":"10.3389\/fmicb.2016.00448"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_028_w2aab3b7d120b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000;28:68\u201373.","DOI":"10.1007\/s150100050049"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_029_w2aab3b7d120b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Jereb M, Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr 2006;118:170\u20134.","DOI":"10.1007\/s00508-006-0563-8"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_030_w2aab3b7d120b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Masia M, Padilla S, Ortiz de la Tabla V, Gonzalez M, Bas C, Gutierrez F. Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: a single-arm clinical trial. PLoS One 2017;12:e0175634.","DOI":"10.1371\/journal.pone.0175634"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_031_w2aab3b7d120b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Curbelo J, Luquero Bueno S, Galvan-Roman JM, Ortega-Gomez M, Rajas O, Fernandez-Jimenez G, et al. Inflammation biomarkers in blood as mortality predictors in community-acquired pneumonia admitted patients: Importance of comparison with neutrophil count percentage or neutrophil-lymphocyte ratio. PLoS One 2017;12:e0173947.","DOI":"10.1371\/journal.pone.0173947"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_032_w2aab3b7d120b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Ishida T, Miyashita N, Nakahama C. Clinical differentiation of atypical pneumonia using Japanese guidelines. Respirology 2007;12:104\u201310.","DOI":"10.1111\/j.1440-1843.2006.00927.x"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_033_w2aab3b7d120b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Bellmann-Weiler R, Ausserwinkler M, Kurz K, Theurl I, Weiss G. Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia. J Clin Microbiol 2010;48:1915\u20137.","DOI":"10.1128\/JCM.01348-09"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_034_w2aab3b7d120b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Fiumefreddo R, Zaborsky R, Haeuptle J, Christ-Crain M, Trampuz A, Steffen I, et al. Clinical predictors for Legionella in patients presenting with community-acquired pneumonia to the emergency department. BMC Pulmonary Med 2009;9:4.","DOI":"10.1186\/1471-2466-9-4"},{"key":"2023033110193596755_j_cclm-2019-0194_ref_035_w2aab3b7d120b1b6b1ab2b2c35Aa","doi-asserted-by":"crossref","unstructured":"Marchello C, Dale AP, Thai TN, Han DS, Ebell MH. Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: a meta-analysis. Ann Fam Med 2016;14:552\u201366.","DOI":"10.1370\/afm.1993"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2019.57.issue-10\/cclm-2019-0194\/cclm-2019-0194.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0194\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0194\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:49:39Z","timestamp":1680263379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0194\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,3,23]]},"published-print":{"date-parts":[[2019,9,25]]}},"alternative-id":["10.1515\/cclm-2019-0194"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2019-0194","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,9]]}}}